Particle.news
Download on the App Store
40 ARTICLES
·
1h ago

EU-Cleared Blood Test Forecasts Alzheimer’s Progression as Spain Prepares Therapy Rollout

Hospitals begin validation studies to enable blood-based screening, requiring infusion capacity plus radiology monitoring for early-stage therapies.

Ildefonso Fernández fue diagnosticado de alzhéimer con 57 años y nueve años después hace una vida "normal"
Grupo de Investigación en Alzheimer y otros trastornos cognitivos (GINEA) y el Grupo de Infección Grave del IIS La Fe
Image
Image

Overview

  • The MAP-AD blood assay, based on mitochondrial DNA methylation analyzed with AI, predicted progression from mild cognitive impairment to Alzheimer’s with 84% accuracy in an iScience study.
  • Developers at Hospital Universitari de Bellvitge and ADmit Therapeutics report the test has received the EU IVDF conformity seal, opening the door to clinical use in Europe.
  • European regulators have authorized disease‑modifying anti‑amyloid drugs this year that can slow decline in early disease, but national approval and access in Spain remain pending.
  • Regional services, including Asturias, are drafting common protocols and building logistics for intravenous delivery and radiological monitoring, with hospital infusion units central to deployment.
  • Experts highlight persistent gaps such as late or missed diagnoses (with estimates of most cases not detected in time) and younger‑onset presentations around 9%, underscoring prevention, cognitive stimulation and caregiver support needs.